epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2024-23-5-92-98epidemiology-2088Research ArticleОБЗОРREVIEWВлияние COVID-19 на микробиоту кишечника беременных женщин (обзор литературы)Effect of COVID-19 on the Gut Microbiota of Pregnant Women (review)https://orcid.org/0000-0002-8820-9903БембееваБ. О.BembeevaB. O.

Бембеева Байр Очировна, заведующая референс-центром по предупреждению распространения биологических угроз института микробиологии, антимикробной терапии и эпидемиологии

117997, Москва, ул. Академика Опарина, д. 4. +7 (962) 728-21-35

Bayr O. Bembeeva – Head-doctor-bacteriologist of the Reference Center of the Prevention of Biological Threats at the Institute of Microbiology, Antimicrobial Therapy and Epidemiology

4, Oparin st., Moscow, 117997, Russia. +7 (962) 728-21-35

b_bembeeva@oparina4.ruhttps://orcid.org/0000-0002-4126-9730ПрипутневичТ. В.PriputnevichT. V.

Татьяна Валерьевна Припутневич – член-корр. РАН, д. м. н., доцент, директор института микробиологии, антимикробной терапии и эпидемиологии

Москва

Tatyna V. Priputnevich – Dr. Sci. (Med.), Corresponding Members of the RAS, Director of the institute of microbiology, antimicrobial therapy and epidemiology

Moscow

priput1@gmail.comhttps://orcid.org/0000-0003-1116-138XДолгушинаН. В.DolgushinaN. V.

Наталия Витальевна Долгушина – д. м. н., профессор, заместитель директора, руководитель департамента организации научной деятельности

Москва

Nataliy V. Dolgushina – Dr. Sci. (Med.), Professor, Deputy Director – Head of the Department for Organization of Scientific Activities

Moscow

n_dolgushina@oparina4.ruФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В. И. Кулакова» Минздрава РоссииРоссияNational Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov of Ministry of Healthcare of Russian FederationRussian Federation2024071120242359298Copyright © Бембеева Б.О., Припутневич Т.В., Долгушина Н.В., 20242024Бембеева Б.О., Припутневич Т.В., Долгушина Н.В.Bembeeva B.O., Priputnevich T.V., Dolgushina N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/2088

Актуальность. Пандемия COVID-19 показала, что беременные женщины находятся в группе риска по инфицированию и тяжелому течению заболевания. Цель. Оценить результаты изучения изменения состава микробиоты кишечника у беременных женщин с возникновением воспалительных изменений в кишечнике, в том числе под действием вируса SARS-CoV-2, а также влияния на развитие тяжелого течения COVID-19, особенно в третьем триместре беременности. Заключение. У беременных женщин часто возникают гастроинтестинальные симптомы как в период разгара заболевания, так и в течение 90 дней после выздоровления. Данный обзор литературы посвящен изучению влияния вируса SARS-CoV-2 на микробиоту кишечника беременных женщин, поскольку множество исследований подтверждает изменения состава микробиоты кишечника при COVID-19, зависимость тяжести течения инфекции от состава микробиоты кишечника и персистенцию вируса в толще кишечника после выздоровления. Остается открытым вопрос, изменяется ли состав микробиоты кишечника у беременных женщин и новорожденных при COVID-19, и возможно ли корректировать состояние дисбиоза кишечника при COVID-19 пробиотиками с целью профилактики и лечения беременных женщин и новорожденных.

The Novel coronavirus infection (COVID-19) pandemic has shown that pregnant women are at risk for infection and severe COVID- 19. Pregnant women often experience gastrointestinal symptoms both during the peak of the disease and within 90 days after recovery. This review is devoted to the study of the effect of the SARS-CoV-2 virus on the gut microbiota of pregnant women. Since many studies confirm changes in the composition of the gut microbiota in COVID-19, the dependence of the severity of the course of infection on the composition of the gut microbiota, and the persistence of the virus in the gut after recovery. The question remains whether the composition of the intestinal microbiota changes in pregnant women and newborns during COVID-19, and whether it is possible to correct the state of intestinal dysbiosis during COVID-19 with probiotics for the purpose of prevention and treatment of pregnant women and newborns.

обзорCOVID-19SARS-CoV-2беременные женщиныкишечная микробиотапробиотикиreviewCOVID-19SARS-CoV-2pregnant womengut microbiotaSCFAReferencesLiu Y., Chen H., Tang K., et al. Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy. The Journal of infection. 2020. P. 30109-2. doi: 10.1016/j.jinf.2020.02.028.Liu Y., Chen H., Tang K., et al. Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy. The Journal of infection. 2020. P. 30109-2. doi: 10.1016/j.jinf.2020.02.028.Metz T. D., Clifton R. G., Hugheset B. L., et al. Disease severity and perinatal outcomes of pregnant patients with Coronavirus disease 2019 (COVID-19). Obstetrics and gynecol- ogy. 2021. Vol. 137, No. 4. P. 571–580. doi: 10.1097/AOG.0000000000004339.Metz T. D., Clifton R. G., Hugheset B. L., et al. Disease severity and perinatal outcomes of pregnant patients with Coronavirus disease 2019 (COVID-19). Obstetrics and gynecol- ogy. 2021. Vol. 137, No. 4. P. 571–580. doi: 10.1097/AOG.0000000000004339.Marchand G., Patil A. S., Masoud A. T., et al. Systematic review and meta-analysis of COVID-19 maternal and neonatal clinical features and pregnancy outcomes up to June 3, 2021. AJOG Global Reports. 2022. Vol. 2, No. 1. P. 100049. doi: 10.1016/j.xagr.2021.100049.Marchand G., Patil A. S., Masoud A. T., et al. Systematic review and meta-analysis of COVID-19 maternal and neonatal clinical features and pregnancy outcomes up to June 3, 2021. AJOG Global Reports. 2022. Vol. 2, No. 1. P. 100049. doi: 10.1016/j.xagr.2021.100049.DeSisto C. L., Wallace B., Simeone R. M., et al. Risk for stillbirth among women with and without COVID -19 at delivery hospitalization - United States, march 2020 – septem- ber 2021. MMWR Morb Mortal Wkly Rep. 2021. Vol. 70, No. 47. P. 1640–1645. doi: 10.15585/mmwr.mm7047e1.DeSisto C. L., Wallace B., Simeone R. M., et al. Risk for stillbirth among women with and without COVID -19 at delivery hospitalization - United States, march 2020 – septem- ber 2021. MMWR Morb Mortal Wkly Rep. 2021. Vol. 70, No. 47. P. 1640–1645. doi: 10.15585/mmwr.mm7047e1.Male V. SARS-CoV-2 infection and COVID-19 vaccination in pregnancy. Nat Rev Immunol. 2022. Vol. 22, No. 5. P. 277–282. doi: 10.1038/s41577-022-00703-6.Male V. SARS-CoV-2 infection and COVID-19 vaccination in pregnancy. Nat Rev Immunol. 2022. Vol. 22, No. 5. P. 277–282. doi: 10.1038/s41577-022-00703-6.Edlow A. G., Castro V. M., Shook L. L., et al. Neurodevelopmental outcomes at 1 year in infants of mothers who tested positive for SARS-CoV-2 during pregnancy. JAMA Netw Open. 2022. Vol. 5, No. 6. P. e2215787. doi: 10.1001/jamanetworkopen.2022.15787.Edlow A. G., Castro V. M., Shook L. L., et al. Neurodevelopmental outcomes at 1 year in infants of mothers who tested positive for SARS-CoV-2 during pregnancy. JAMA Netw Open. 2022. Vol. 5, No. 6. P. e2215787. doi: 10.1001/jamanetworkopen.2022.15787.Ostaff M. J., Stange E. F., Wehkamp J. Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol Med. 2013. Vol. 5, No. 10. P. 1465–83. doi: 10.1002/emmm.201201773.Ostaff M. J., Stange E. F., Wehkamp J. Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol Med. 2013. Vol. 5, No. 10. P. 1465–83. doi: 10.1002/emmm.201201773.Edwards S. M., Cunningham S. A., Dunlop A. L., et al. The Maternal Gut Microbiome during Pregnancy. MCN The American Journal of Maternal/Child Nursing. 2017. Vol. 42, No. 6. P. 310–317. doi: 10.1097/NMC.0000000000000372.Edwards S. M., Cunningham S. A., Dunlop A. L., et al. The Maternal Gut Microbiome during Pregnancy. MCN The American Journal of Maternal/Child Nursing. 2017. Vol. 42, No. 6. P. 310–317. doi: 10.1097/NMC.0000000000000372.Amir M., Brown J. A., Rager S. L., et al. Maternal microbiome and infections in pregnancy. Microorganisms. 2020. Vol. 8, No. 12. P. 1996. doi: 10.3390/microorganisms8121996.Amir M., Brown J. A., Rager S. L., et al. Maternal microbiome and infections in pregnancy. Microorganisms. 2020. Vol. 8, No. 12. P. 1996. doi: 10.3390/microorganisms8121996.Greenhalgh T., Jimenez J. L., Prather K. A., et al. Ten scientific reasons in support of airborne transmission of SARS-CoV-2. The Lancet. 2021. Vol. 397, No. P. 1603–1605. doi: 10.1016/S0140-6736(21)00869-2.Greenhalgh T., Jimenez J. L., Prather K. A., et al. Ten scientific reasons in support of airborne transmission of SARS-CoV-2. The Lancet. 2021. Vol. 397, No. P. 1603–1605. doi: 10.1016/S0140-6736(21)00869-2.De R., Dutta S. Role of the Microbiome in the Pathogenesis of COVID-19. Frontiers in Cellular and Infection Microbiology. 2022. Vol. 12. P. 736397. doi: 10.3389/fcimb.2022.736397.De R., Dutta S. Role of the Microbiome in the Pathogenesis of COVID-19. Frontiers in Cellular and Infection Microbiology. 2022. Vol. 12. P. 736397. doi: 10.3389/fcimb.2022.736397.https://gogov.ru/covid-19/worldhttps://gogov.ru/covid-19/worldWorld Health Organization. Tracking SARS-CoV-2 variants. Доступно на Available at: https://www.who.int/activities/tracking-SARS-CoV-2-variants0.World Health Organization. Tracking SARS-CoV-2 variants. Доступно на Available at: https://www.who.int/activities/tracking-SARS-CoV-2-variants0.Mizrahi B., Sudry T., Flaks-Manov N., et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023. Vol. 380. P. e072529. doi: 10.1136/bmj-2022-072529.Mizrahi B., Sudry T., Flaks-Manov N., et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023. Vol. 380. P. e072529. doi: 10.1136/bmj-2022-072529.Wang K., Chen W., Zhou Y., et al. SARS-CoV-2 invades host cells via a Novel route: CD147-spike protein. bioRxiv. 2020. doi: https://doi.org/10.1101/2020.03.14.988345.Wang K., Chen W., Zhou Y., et al. SARS-CoV-2 invades host cells via a Novel route: CD147-spike protein. bioRxiv. 2020. doi: https://doi.org/10.1101/2020.03.14.988345.Xu R., Lu R., Zhang T., et al. Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults. Commun Biol. 2021. Vol. 4, No. 1. doi: 10.1038/s42003-021-01796-w.Xu R., Lu R., Zhang T., et al. Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults. Commun Biol. 2021. Vol. 4, No. 1. doi: 10.1038/s42003-021-01796-w.Dolk H. SARS-COV-2 pandemic: The significance of underlying conditions. Occupational Medicine. 2020. Vol. 70, No. 5. P. 352–353. doi: 10.1093/occmed/kqaa084.Dolk H. SARS-COV-2 pandemic: The significance of underlying conditions. Occupational Medicine. 2020. Vol. 70, No. 5. P. 352–353. doi: 10.1093/occmed/kqaa084.Leon D. A., Shkolnikov V. M., Smeeth L., et al. COVID-19: a need for real-time monitoring of weekly excess deaths. The Lancet. 2020. Vol. 395, No. 10234. P. 30933–8. doi: 10.1016/S0140-6736(20)30933-8.Leon D. A., Shkolnikov V. M., Smeeth L., et al. COVID-19: a need for real-time monitoring of weekly excess deaths. The Lancet. 2020. Vol. 395, No. 10234. P. 30933–8. doi: 10.1016/S0140-6736(20)30933-8.Salem D., Katranji F., Bakdash T. COVID-19 infection in pregnant women: Review of maternal and fetal outcomes. International Journal of Gynecology and Obstetrics. 2021. Vol. 152, No. 3. P. 291–298. doi: 10.1002/ijgo.13533.Salem D., Katranji F., Bakdash T. COVID-19 infection in pregnant women: Review of maternal and fetal outcomes. International Journal of Gynecology and Obstetrics. 2021. Vol. 152, No. 3. P. 291–298. doi: 10.1002/ijgo.13533.Koester S. T., Li N., Lachance D. M., et al. Variability in digestive and respiratory tract Ace2 expression is associated with the microbiome. PLoS One. 2021. Vol. 16, No. 3. P. e0248730. doi: 10.1371/journal.pone.0248730.Koester S. T., Li N., Lachance D. M., et al. Variability in digestive and respiratory tract Ace2 expression is associated with the microbiome. PLoS One. 2021. Vol. 16, No. 3. P. e0248730. doi: 10.1371/journal.pone.0248730.Zuo T.., Zhang F., Lui G. C. Y., et al, Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020. Vol. 159, No. 3. P. 944–955. doi: 10.1053/j.gastro.2020.05.048.Zuo T.., Zhang F., Lui G. C. Y., et al, Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020. Vol. 159, No. 3. P. 944–955. doi: 10.1053/j.gastro.2020.05.048.Bingula R., Filaire M., Radosevic-Robin N., et al. Desired Turbulence? Gut-Lung Axis, Immunity, and Lung Cancer. Journal of Oncology. 2017. Vol. 2017. P. 5035371. doi: 10.1155/2017/5035371.Bingula R., Filaire M., Radosevic-Robin N., et al. Desired Turbulence? Gut-Lung Axis, Immunity, and Lung Cancer. Journal of Oncology. 2017. Vol. 2017. P. 5035371. doi: 10.1155/2017/5035371.Groves H. T., Higham S. L., Moffatt M. F., et al. Respiratory viral infection alters the gut microbiota by inducing inappetence. mBio. 2020. Vol. 11, No. 1. doi: 10.1128/mBio.03236-19.Groves H. T., Higham S. L., Moffatt M. F., et al. Respiratory viral infection alters the gut microbiota by inducing inappetence. mBio. 2020. Vol. 11, No. 1. doi: 10.1128/mBio.03236-19.Wang M. K., Yue H. Y., Cai J., et al. COVID-19 and the digestive system: A comprehensive review. World J Clin Cases. 2021. Vol. 9, No. 16. P. 3796–3813. doi: 10.12998/wjcc.v9.i16.3796.Wang M. K., Yue H. Y., Cai J., et al. COVID-19 and the digestive system: A comprehensive review. World J Clin Cases. 2021. Vol. 9, No. 16. P. 3796–3813. doi: 10.12998/wjcc.v9.i16.3796.Weng J., Li Y., Li J., et al. Gastrointestinal sequelae 90 days after discharge for COVID-19. The Lancet Gastroenterology and Hepatology. 2021. Vol. 6, No. 5. P. 344–346. doi: 10.1016/S2468-1253(21)00076-5.Weng J., Li Y., Li J., et al. Gastrointestinal sequelae 90 days after discharge for COVID-19. The Lancet Gastroenterology and Hepatology. 2021. Vol. 6, No. 5. P. 344–346. doi: 10.1016/S2468-1253(21)00076-5.Ren Z., Wang H., Cui G., et al. Alterations in the human oral and gut microbiomes and lipidomics in COVID-19. Gut. 2021. Vol. 70, No. 7. P. 1253–1265. doi: 10.1136/gutjnl-2020-323826.Ren Z., Wang H., Cui G., et al. Alterations in the human oral and gut microbiomes and lipidomics in COVID-19. Gut. 2021. Vol. 70, No. 7. P. 1253–1265. doi: 10.1136/gutjnl-2020-323826.Moreira-Rosário A., Marques C., Pinheiro H., et al. Gut Microbiota Diversity and C-Reactive Protein Are Predictors of Disease Severity in COVID-19 Patients. Front Microbiol. 2021. Vol. 12. P. 705020. doi: 10.3389/fmicb.2021.705020.Moreira-Rosário A., Marques C., Pinheiro H., et al. Gut Microbiota Diversity and C-Reactive Protein Are Predictors of Disease Severity in COVID-19 Patients. Front Microbiol. 2021. Vol. 12. P. 705020. doi: 10.3389/fmicb.2021.705020.Yeoh Y.K., Zuo T., Lui G.C., et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021. Vol. 70, No. 4. P. 698–706. doi: 10.1136/gutjnl-2020-323020.Yeoh Y.K., Zuo T., Lui G.C., et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021. Vol. 70, No. 4. P. 698–706. doi: 10.1136/gutjnl-2020-323020.Yin Y. S., Minacapelli C. D., Parmar V., et al. Alterations of the fecal microbiota in relation to acute COVID-19 infection and recovery. Molecular Biomedicine. 2022. Vol. 3, No. 1. P. 36. doi: 10.1186/s43556-022-00103-1.Yin Y. S., Minacapelli C. D., Parmar V., et al. Alterations of the fecal microbiota in relation to acute COVID-19 infection and recovery. Molecular Biomedicine. 2022. Vol. 3, No. 1. P. 36. doi: 10.1186/s43556-022-00103-1.Upadhyay V., Suryawanshi R., Tasoff P., et al. Mild SARS-CoV-2 infection results in long-lasting microbiota instability. bioRxiv. 2022. doi: 10.1101/2022.12.07.519508.Upadhyay V., Suryawanshi R., Tasoff P., et al. Mild SARS-CoV-2 infection results in long-lasting microbiota instability. bioRxiv. 2022. doi: 10.1101/2022.12.07.519508.Del Valle D. M., Kim-Schulze S., Huang H. H., et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020. Vol. 26, No. 10. P. 1636–1643. doi: 10.1038/s41591-020-1051-9.Del Valle D. M., Kim-Schulze S., Huang H. H., et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020. Vol. 26, No. 10. P. 1636–1643. doi: 10.1038/s41591-020-1051-9.Masoodi M., Peschka M., Schmiedel S., et al. Disturbed lipid and amiNo acid metabolisms in COVID-19 patients. J Mol Med. 2022. Vol. 100, No. 4. P. 555–568. doi: 10.1007/s00109-022-02177-4.Masoodi M., Peschka M., Schmiedel S., et al. Disturbed lipid and amiNo acid metabolisms in COVID-19 patients. J Mol Med. 2022. Vol. 100, No. 4. P. 555–568. doi: 10.1007/s00109-022-02177-4.Mancabelli L., Milani C., Fontana F., et al. Untangling the link between the human gut microbiota composition and the severity of the symptoms of the COVID-19 infection. Environ Microbiol. 2022. Vol. 24, No. 12, P. 6453–6462. doi: 10.1111/1462-2920.16201.Mancabelli L., Milani C., Fontana F., et al. Untangling the link between the human gut microbiota composition and the severity of the symptoms of the COVID-19 infection. Environ Microbiol. 2022. Vol. 24, No. 12, P. 6453–6462. doi: 10.1111/1462-2920.16201.Margolis K. G., Cryan J. F., Mayer E. A. The Microbiota-Gut-Brain Axis: From Motility to Mood. Gastroenterology. 2021. Vol. 160, No. 5. P. 1486–1501. doi: 10.1053/j.gastro.2020.10.066.Margolis K. G., Cryan J. F., Mayer E. A. The Microbiota-Gut-Brain Axis: From Motility to Mood. Gastroenterology. 2021. Vol. 160, No. 5. P. 1486–1501. doi: 10.1053/j.gastro.2020.10.066.Nilsen M., Madelen Saunders C., Leena Angell I., et al. Butyrate levels in the transition from an infant-to an adult-like gut microbiota correlate with bacterial networks associ- ated with eubacterium rectale and rumiNococcus gnavus. Genes (Basel). 2020. Vol. 11, No. 11. P. 1245. doi: 10.3390/genes11111245.Nilsen M., Madelen Saunders C., Leena Angell I., et al. Butyrate levels in the transition from an infant-to an adult-like gut microbiota correlate with bacterial networks associ- ated with eubacterium rectale and rumiNococcus gnavus. Genes (Basel). 2020. Vol. 11, No. 11. P. 1245. doi: 10.3390/genes11111245.Sencio V., Machelart A., Robil C., et al. Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters. Gut Microbes. 2022. Vol. 14, No. 1. P. 2018900. doi: 10.1080/19490976.2021.2018900.Sencio V., Machelart A., Robil C., et al. Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters. Gut Microbes. 2022. Vol. 14, No. 1. P. 2018900. doi: 10.1080/19490976.2021.2018900.Ji J. J., Sun Q. M., Nie D. Y., et al. Probiotics protect against RSV infection by modulating the microbiota-alveolar-macrophage axis. Acta Pharmacol Sin. 2021. Vol. 42, No. 10. P. 1630-1641. doi: 10.1038/s41401-020-00573-5.Ji J. J., Sun Q. M., Nie D. Y., et al. Probiotics protect against RSV infection by modulating the microbiota-alveolar-macrophage axis. Acta Pharmacol Sin. 2021. Vol. 42, No. 10. P. 1630-1641. doi: 10.1038/s41401-020-00573-5.Peery A. F., Crockett S. D., Murphy C. C., et al. Prolonged Impairment of Short-Chain Fatty Acid and L-Isoleucine Biosynthesis in Gut Microbiome in Patients With COVID-19. Gastroenterology. 2022. Vol. 162, No. 2. P. 621-644. doi: 10.1053/j.gastro.2021.10.013.Peery A. F., Crockett S. D., Murphy C. C., et al. Prolonged Impairment of Short-Chain Fatty Acid and L-Isoleucine Biosynthesis in Gut Microbiome in Patients With COVID-19. Gastroenterology. 2022. Vol. 162, No. 2. P. 621-644. doi: 10.1053/j.gastro.2021.10.013.Freedberg D. E., Chang L. Gastrointestinal symptoms in COVID-19: the long and the short of it. Curr Opin Gastroenterol. 2022. Vol. 38, No. 6. P. 555–561. doi: 10.1097/MOG.0000000000000876.Freedberg D. E., Chang L. Gastrointestinal symptoms in COVID-19: the long and the short of it. Curr Opin Gastroenterol. 2022. Vol. 38, No. 6. P. 555–561. doi: 10.1097/MOG.0000000000000876.Redd W. D., Zhou J. C., Hathorn K. E., et al. Prevalence and characteristics of gastrointestinal symptoms in patients with severe acute respiratory syndrome coronavirus 2 infection in the United States: a multicenter cohort study. Gastroenterology. 2020. Vol. 159, No. 2. P. 765–767. doi: 10.1053/j.gastro.2020.04.045.Redd W. D., Zhou J. C., Hathorn K. E., et al. Prevalence and characteristics of gastrointestinal symptoms in patients with severe acute respiratory syndrome coronavirus 2 infection in the United States: a multicenter cohort study. Gastroenterology. 2020. Vol. 159, No. 2. P. 765–767. doi: 10.1053/j.gastro.2020.04.045.Chen Y., Chen L., Deng Q., et al. The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. J Med Virol. 2020. Vol. 92, No. 7. P. 833–840. doi: 10.1002/jmv.25825.Chen Y., Chen L., Deng Q., et al. The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. J Med Virol. 2020. Vol. 92, No. 7. P. 833–840. doi: 10.1002/jmv.25825.Tang A., Tong Z. D., Wang H. L., et al. Detection of novel coronavirus by RT-PCR in stool specimen from asymptomatic child, China. Emerg Infect Dis. 2020. Vol. 26, No. 6. P. 1337–1339. doi: 10.3201/eid2606.200301.Tang A., Tong Z. D., Wang H. L., et al. Detection of novel coronavirus by RT-PCR in stool specimen from asymptomatic child, China. Emerg Infect Dis. 2020. Vol. 26, No. 6. P. 1337–1339. doi: 10.3201/eid2606.200301.Wu X., Liu X., Zhou Y., et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021. Vol. 9, No. 7. P. 747–754. doi: 10.1016/S2213-2600(21)00174-0.Wu X., Liu X., Zhou Y., et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021. Vol. 9, No. 7. P. 747–754. doi: 10.1016/S2213-2600(21)00174-0.Gareau M. G., Barrett K. E. The role of the microbiota-gut-brain axis in post-acute COVID syndrome. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2023. Vol. 324, No. 4. P. 322–328. doi: 10.1152/ajpgi.00293.2022.Gareau M. G., Barrett K. E. The role of the microbiota-gut-brain axis in post-acute COVID syndrome. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2023. Vol. 324, No. 4. P. 322–328. doi: 10.1152/ajpgi.00293.2022.Jensterle M., Herman R., Janež A., et al. The Relationship between COVID-19 and hypothalamic-pituitary-adrenal axis: a large spectrum from glucocorticoid insufficiency to excess-The CAPISCO International Expert Panel. International Journal of Molecular Sciences. 2022. Vol. 23, No. 13. P. 7326. doi: 10.3390/ijms23137326.Jensterle M., Herman R., Janež A., et al. The Relationship between COVID-19 and hypothalamic-pituitary-adrenal axis: a large spectrum from glucocorticoid insufficiency to excess-The CAPISCO International Expert Panel. International Journal of Molecular Sciences. 2022. Vol. 23, No. 13. P. 7326. doi: 10.3390/ijms23137326.Ancona G., Alagna L., Alteri C., et al. Gut and airway microbiota dysbiosis and their role in COVID-19 and long-COVID. Front ImmuNol. 2023. Vol. 14. doi: 10.3389/fimmu.2023.1080043.Ancona G., Alagna L., Alteri C., et al. Gut and airway microbiota dysbiosis and their role in COVID-19 and long-COVID. Front ImmuNol. 2023. Vol. 14. doi: 10.3389/fimmu.2023.1080043.Dashraath P., Wong J. L. J, Lim M. X. K., et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol. 2020. Vol. 222, No. 6. P. 521–531. doi: 10.1016/j.ajog.2020.03.021.Dashraath P., Wong J. L. J, Lim M. X. K., et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol. 2020. Vol. 222, No. 6. P. 521–531. doi: 10.1016/j.ajog.2020.03.021.Park S. K., Lee C. W., Park D. I., et al. Detection of SARS-CoV-2 in fecal samples from patients with asymptomatic and mild COVID-19 in Korea. Clinical Gastroenterology and Hepatology. 2021. Vol. 19, No. 7. P. 1387–1394. doi: 10.1016/j.cgh.2020.06.005.Park S. K., Lee C. W., Park D. I., et al. Detection of SARS-CoV-2 in fecal samples from patients with asymptomatic and mild COVID-19 in Korea. Clinical Gastroenterology and Hepatology. 2021. Vol. 19, No. 7. P. 1387–1394. doi: 10.1016/j.cgh.2020.06.005.Shokri-Afra H., Alikhani A., Moradipoodeh B., et al. Elevated fecal and serum calprotectin in COVID-19 are not consistent with gastrointestinal symptoms. Sci Rep. 2021. Vol. 11. P. 22001. doi: 10.1038/s41598-021-01231-4.Shokri-Afra H., Alikhani A., Moradipoodeh B., et al. Elevated fecal and serum calprotectin in COVID-19 are not consistent with gastrointestinal symptoms. Sci Rep. 2021. Vol. 11. P. 22001. doi: 10.1038/s41598-021-01231-4.Livanos A. E., Jha D., Cossarini F., et al. Intestinal host response to SARS-CoV-2 infection and COVID-19 outcomes in patients with gastrointestinal symptoms. Gastroenterology. 2021. Vol. 160, No. 7. P. 2435–2450. doi: 10.1053/j.gastro.2021.02.056.Livanos A. E., Jha D., Cossarini F., et al. Intestinal host response to SARS-CoV-2 infection and COVID-19 outcomes in patients with gastrointestinal symptoms. Gastroenterology. 2021. Vol. 160, No. 7. P. 2435–2450. doi: 10.1053/j.gastro.2021.02.056.Su Q., Lau R. I., Liu Q., Chan F. K. L., et al. Post-acute COVID-19 syndrome and gut dysbiosis linger beyond 1 year after SARS-CoV-2 clearance. Gut. 2022. Vol. 72, No. 6. P. 1230–1232. doi: 10.1136/gutjnl-2022-328319.Su Q., Lau R. I., Liu Q., Chan F. K. L., et al. Post-acute COVID-19 syndrome and gut dysbiosis linger beyond 1 year after SARS-CoV-2 clearance. Gut. 2022. Vol. 72, No. 6. P. 1230–1232. doi: 10.1136/gutjnl-2022-328319.Gibson G. R., Hutkins R., Sanders M. E., et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature Reviews Gastroenterology and Hepatology. 2017. Vol. 14, No. 8. P. 491-502. doi: 10.1038/nrgastro.2017.75.Gibson G. R., Hutkins R., Sanders M. E., et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature Reviews Gastroenterology and Hepatology. 2017. Vol. 14, No. 8. P. 491-502. doi: 10.1038/nrgastro.2017.75.Marinova V. Y., Rasheva I. K., Kizheva Y. K. Microbiological quality of probiotic dietary supplements. BiotechNology and BiotechNological Equipment. 2019. Vol. 33, No. 1. P. 834–841. doi: 10.1080/13102818.2019.1621208.Marinova V. Y., Rasheva I. K., Kizheva Y. K. Microbiological quality of probiotic dietary supplements. BiotechNology and BiotechNological Equipment. 2019. Vol. 33, No. 1. P. 834–841. doi: 10.1080/13102818.2019.1621208.Kim S. K., Guevarra R. B., Kim Y. T., et al. Role of probiotics in human gut microbiome-associated diseases. J Microbiol Biotechnol. 2019. Vol. 29, No. 9. P. 1335–1340. doi: 10.4014/jmb.1906.06064.Kim S. K., Guevarra R. B., Kim Y. T., et al. Role of probiotics in human gut microbiome-associated diseases. J Microbiol Biotechnol. 2019. Vol. 29, No. 9. P. 1335–1340. doi: 10.4014/jmb.1906.06064.Etienne-Mesmin L., Chassaing B., Desvaux M., et al. Experimental models to study intestinal microbes–mucus interactions in health and disease. FEMS Microbiology Reviews. 2019. Vol. 43, No. 5. P. 457-489. doi: 10.1093/femsre/fuz013.Etienne-Mesmin L., Chassaing B., Desvaux M., et al. Experimental models to study intestinal microbes–mucus interactions in health and disease. FEMS Microbiology Reviews. 2019. Vol. 43, No. 5. P. 457-489. doi: 10.1093/femsre/fuz013.Lehtoranta L., Pitkäranta A., Korpela R. Probiotics in respiratory virus infections. European Journal of Clinical Microbiology and Infectious Diseases. 2014. Vol. 33, No. 8. P. 1289–302. doi: 10.1007/s10096-014-2086-y.Lehtoranta L., Pitkäranta A., Korpela R. Probiotics in respiratory virus infections. European Journal of Clinical Microbiology and Infectious Diseases. 2014. Vol. 33, No. 8. P. 1289–302. doi: 10.1007/s10096-014-2086-y.Li Q., Cheng F., Xu Q., et al. The role of probiotics in coronavirus disease-19 infection in Wuhan: A retrospective study of 311 severe patients. Int Immunopharmacol. 2021. Vol. 95. P. 107531 doi: 10.1016/j.intimp.2021.107531.Li Q., Cheng F., Xu Q., et al. The role of probiotics in coronavirus disease-19 infection in Wuhan: A retrospective study of 311 severe patients. Int Immunopharmacol. 2021. Vol. 95. P. 107531 doi: 10.1016/j.intimp.2021.107531.Gutiérrez-Castrellón P., Gandara-Martí T., Abreu Y., et al. Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes. 2022. Vol. 14, No. 1. P. 2018899. doi: 10.1080/19490976.2021.2018899.Gutiérrez-Castrellón P., Gandara-Martí T., Abreu Y., et al. Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes. 2022. Vol. 14, No. 1. P. 2018899. doi: 10.1080/19490976.2021.2018899.Rather I. A., Choi S. B., Kamli M. R., et al. Potential adjuvant therapeutic effect of lactobacillus plantarum probio-88 postbiotics against SARS-COV-2. Vaccines (Basel). 2021. Vol. 9, No. 10. P. 1067. doi: 10.3390/vaccines9101067.Rather I. A., Choi S. B., Kamli M. R., et al. Potential adjuvant therapeutic effect of lactobacillus plantarum probio-88 postbiotics against SARS-COV-2. Vaccines (Basel). 2021. Vol. 9, No. 10. P. 1067. doi: 10.3390/vaccines9101067.Desheva Y., Leontieva G., Kramskaya T., et al. Developing a live probiotic vaccine based on the enterococcus faecium l3 strain expressing influenza neuraminidase. Microorganisms. 2021. Vol. 9, No. 12. P. 2446. doi: 10.3390/microorganisms9122446.Desheva Y., Leontieva G., Kramskaya T., et al. Developing a live probiotic vaccine based on the enterococcus faecium l3 strain expressing influenza neuraminidase. Microorganisms. 2021. Vol. 9, No. 12. P. 2446. doi: 10.3390/microorganisms9122446.

The authors declare that there are no conflicts of interest present.